Leerink Partnrs Has Bullish Outlook for ZNTL FY2024 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Stock analysts at Leerink Partnrs raised their FY2024 EPS estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn ($2.68) per share for the year, up from their prior forecast of ($3.05). The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.76) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals' Q4 2024 earnings at ($1.01) EPS, FY2025 earnings at ($3.47) EPS, FY2026 earnings at ($3.39) EPS and FY2027 earnings at ($3.14) EPS.

A number of other equities analysts also recently commented on the company. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday. Wedbush upgraded Zentalis Pharmaceuticals from an "underperform" rating to a "neutral" rating and set a $4.00 price target for the company in a research note on Monday, August 12th. Guggenheim cut their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Friday. Finally, Oppenheimer reissued an "outperform" rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $10.00.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock traded down $0.42 on Monday, reaching $3.05. 1,470,923 shares of the company were exchanged, compared to its average volume of 1,330,244. Zentalis Pharmaceuticals has a 1-year low of $2.66 and a 1-year high of $18.07. The company has a market cap of $217.34 million, a P/E ratio of -1.24 and a beta of 1.74. The stock's 50 day moving average price is $3.42 and its 200-day moving average price is $5.38.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.36.

Institutional Trading of Zentalis Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Decheng Capital LLC boosted its stake in Zentalis Pharmaceuticals by 46.2% in the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company's stock worth $12,558,000 after buying an additional 970,859 shares during the last quarter. Verition Fund Management LLC boosted its stake in Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock worth $5,536,000 after buying an additional 951,500 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Zentalis Pharmaceuticals by 20.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company's stock worth $54,999,000 after buying an additional 585,644 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company's stock worth $2,706,000 after buying an additional 399,745 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its stake in Zentalis Pharmaceuticals by 138.5% in the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company's stock worth $2,240,000 after buying an additional 353,384 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.